ES2721477T3 - Materiales y métodos para evaluar la progresión del cáncer de próstata - Google Patents

Materiales y métodos para evaluar la progresión del cáncer de próstata Download PDF

Info

Publication number
ES2721477T3
ES2721477T3 ES15739712T ES15739712T ES2721477T3 ES 2721477 T3 ES2721477 T3 ES 2721477T3 ES 15739712 T ES15739712 T ES 15739712T ES 15739712 T ES15739712 T ES 15739712T ES 2721477 T3 ES2721477 T3 ES 2721477T3
Authority
ES
Spain
Prior art keywords
equal
patient
fgfr1
gain
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15739712T
Other languages
English (en)
Inventor
Ying Zhang
Ekaterina Pestova
Jing Du
Ping Liu
Tracey Colpitts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Molecular Inc
Original Assignee
Abbott Molecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Molecular Inc filed Critical Abbott Molecular Inc
Application granted granted Critical
Publication of ES2721477T3 publication Critical patent/ES2721477T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un método para distinguir entre un paciente con adenocarcinoma prostático agresivo y un paciente con adenocarcinoma prostático indolente, método que comprende: (a) poner en contacto una muestra del paciente con un conjunto de sondas etiquetadas de manera detectable que comprende una sonda específica de locus para MYC, una sonda específica de locus para FGFR1 y una sonda de separación para ERG, en condiciones de hibridación, en donde se utiliza la sonda específica de locus para FGFR1 para determinar el % de pérdida de FGFR1, (b) determinar la presencia de una anomalía cromosómica en la muestra, en donde (i) un % de ganancia de MYC (el % de ganancia es el % de células con números de copias de MYC > 2) superior o igual a dos hasta inferior o igual a 30, (ii) un % de pérdida de FGFR1 (el % de pérdida es el % de células con números de copias de FGFR < 2) superior o igual a 15 hasta inferior o igual a 40, (iii) un % de ganancia de FGFR1 (el % de ganancia es el % de células con números de copias de FGFR > 2) superior o igual a dos hasta inferior o igual a 46, y/o (iv) un ERG 2+Edel superior o igual a uno hasta inferior o igual a 30, indica que el paciente tiene un alto riesgo de desarrollar un adenocarcinoma prostático agresivo y en donde la ausencia de cualquiera de (i)-(iv) anterior indica que el paciente tiene un adenocarcinoma prostático indolente, tras lo cual un paciente con adenocarcinoma prostático agresivo se distingue de un paciente con adenocarcinoma prostático indolente.
ES15739712T 2014-07-03 2015-07-01 Materiales y métodos para evaluar la progresión del cáncer de próstata Active ES2721477T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462020990P 2014-07-03 2014-07-03
PCT/US2015/038761 WO2016004165A1 (en) 2014-07-03 2015-07-01 Materials and methods for assessing progression of prostate cancer

Publications (1)

Publication Number Publication Date
ES2721477T3 true ES2721477T3 (es) 2019-07-31

Family

ID=53716562

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15739712T Active ES2721477T3 (es) 2014-07-03 2015-07-01 Materiales y métodos para evaluar la progresión del cáncer de próstata

Country Status (6)

Country Link
US (3) US9994912B2 (es)
EP (2) EP3164504B1 (es)
JP (1) JP6683633B2 (es)
CN (1) CN106574307A (es)
ES (1) ES2721477T3 (es)
WO (1) WO2016004165A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017378320B2 (en) * 2016-12-13 2024-01-04 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating cancers containing fusion genes
WO2019169336A1 (en) * 2018-03-02 2019-09-06 The Johns Hopkins University Methods for prostate cancer detection
CN112534439A (zh) 2018-07-27 2021-03-19 文塔纳医疗系统公司 用于自动化原位杂交分析的系统
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
DE69330750T2 (de) 1992-03-04 2002-07-04 Univ California Vergleichende genomhybridisierung
US5830645A (en) 1994-12-09 1998-11-03 The Regents Of The University Of California Comparative fluorescence hybridization to nucleic acid arrays
US5658730A (en) 1994-12-23 1997-08-19 Ctrc Research Foundation Methods of human prostate cancer diagnosis
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6613510B2 (en) 1999-04-28 2003-09-02 Mayo Foundation For Medical Education And Research Methods and probe sets for determining prostate cancer prognosis
EP1512755A3 (en) 1999-06-10 2007-11-21 Sloan-Kettering Institute For Cancer Research Markers for prostate cancer
DE10063112A1 (de) 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Erhöhung der klinischen Spezifität bei der Detektion von Tumoren und ihren Vorstufen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
WO2002100246A2 (en) 2001-06-12 2002-12-19 Board Of Regents, The University Of Texas System Methods of detecting, diagnosing and treating cancer and identifying neoplastic progression
US20070237770A1 (en) 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
DK2799555T3 (en) 2002-03-13 2017-05-22 Genomic Health Inc Gene Expression Profiling in Tumor Tissue Biopsies
US7604965B2 (en) 2003-04-03 2009-10-20 Fluidigm Corporation Thermal reaction device and method for using the same
AU2005212401A1 (en) 2004-02-06 2005-08-25 Health Research, Inc. Method of prognosis of metastasis by detection of FRA12E fragile site within the SMRT gene/locus at chromosome 12q24
CA2992180C (en) 2004-05-07 2021-02-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
WO2006110585A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes (prlr)
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US7812143B2 (en) 2006-03-31 2010-10-12 Memorial Sloan-Kettering Cancer Center Biomarkers for cancer treatment
FI20060751A0 (fi) 2006-08-23 2006-08-23 Valtion Teknillinen Menetelmä prostatasyövän hoitoon ja mainitusta menetelmästä hyödyntävien potilaiden seulonta
WO2008121132A2 (en) 2007-03-30 2008-10-09 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for identification, monitoring, and treatment of prostate cancer
CA2692793C (en) 2007-07-06 2014-05-20 The Regents Of The University Of Michigan Mipol1-etv1 gene rearrangements
BRPI0816393A2 (pt) 2007-09-07 2015-03-03 Fluidigm Corp Método para determinar o número de cópias relativo de uma sequência de polinucleotídeo alvo em um genoma de um indivíduo
EP2215267A1 (en) 2007-11-06 2010-08-11 Source Precision Medicine, Inc. Gene expression profiling for identification of cancer
JP5781922B2 (ja) 2008-04-10 2015-09-24 ザ ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン，インコーポレーテッド Ｅｒｇ遺伝子発現における前立腺癌特異的変化ならびにそれらの変化に基づく検出および治療方法
WO2009140741A1 (en) 2008-05-23 2009-11-26 The University Of Queensland Agents and methods for diagnosing the presence or risk of prostate cancer
ES2668555T3 (es) 2008-05-27 2018-05-18 Dako Denmark A/S Composiciones y métodos para la detección de aberraciones cromosómicas con tampones de hibridación novedosos
GB0809689D0 (en) 2008-05-28 2008-07-02 Cancer Res Inst Royal Markers for prostate cancee
EP2315858A2 (en) 2008-07-08 2011-05-04 Source Precision Medicine, Inc. Gene expression profiling for predicting the survivability of prostate cancer subjects
KR20110052627A (ko) 2008-07-16 2011-05-18 다나-파버 캔서 인스티튜트 인크. 전립선암과 관련된 시그너처 및 ｐｃ결정인자 및 그의 사용 방법
WO2010056993A2 (en) 2008-11-14 2010-05-20 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
CN102639709A (zh) 2009-01-09 2012-08-15 密歇根大学董事会 癌症中的复现性基因融合体
AU2010204741B2 (en) 2009-01-14 2016-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
WO2010099577A1 (en) 2009-03-04 2010-09-10 The University Of Queensland Cancer biomarkers and uses therefor
WO2010102277A2 (en) 2009-03-06 2010-09-10 Cornell University Methods of diagnosing and treating prostate cancer characterized by ndrg1-erg fusion
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US20130005837A1 (en) 2009-12-31 2013-01-03 Emory University Cancer biomarkers to predict recurrence and metastatic potential
CA2696545C (en) * 2010-03-15 2019-08-06 Queen's University At Kingston Methods, probe sets, and kits for detection of deletion of tumor suppressor genes by fluorescence in situ hybridization
ES2621812T3 (es) * 2010-05-10 2017-07-05 Mayo Foundation For Medical Education And Research Detección de anomalías cromosómicas asociadas con el cáncer endometrial
GB201012590D0 (en) 2010-07-27 2010-09-08 Queen Mary & Westfield College Methods for diagnosing cancer
EP2678446B1 (en) 2011-02-24 2017-06-28 Ventana Medical Systems, Inc. Presence of erg gene rearrangements and protein over-expression in low grade pin (lg-pin) in prostate biopsies
BR112013023050A8 (pt) 2011-03-09 2018-09-25 G Pestell Richard antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal
WO2012125805A2 (en) 2011-03-17 2012-09-20 The Brigham And Women's Hospital, Inc. Protein biomarkers for the diagnosis of prostate cancer
CA2833534A1 (en) * 2011-04-18 2012-10-26 Cornell University Molecular subtyping, prognosis and treatment of prostate cancer
WO2013033073A1 (en) 2011-08-31 2013-03-07 Ventana Medical Systems, Inc. Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
BR122015032159A2 (pt) 2011-12-30 2019-08-27 Abbott Molecular Inc método para detectar câncer de próstata utilizando conjunto de sondas compreendendo sondas lócus específicas para myc e para homólogo de fosfatase e tensina (pten) e sondas centroméricas para cromossomos 7, 8 e 10, bem como conjunto de sondas e kit
WO2013173463A1 (en) 2012-05-15 2013-11-21 Cornell University Erg/tff3/hmwck triple immunostain for detection of prostate cancer
EP2695950A1 (en) 2012-08-10 2014-02-12 Blackfield AG Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
WO2014028907A1 (en) 2012-08-16 2014-02-20 The Trustees Of Columbia University In The City Of New York Diagnostic markers of indolent prostate cancer
US9994908B2 (en) * 2013-03-14 2018-06-12 Abbott Molecular Inc. Materials and methods for assessment of colorectal adenoma

Also Published As

Publication number Publication date
US20160002735A1 (en) 2016-01-07
CN106574307A (zh) 2017-04-19
US10604812B2 (en) 2020-03-31
WO2016004165A1 (en) 2016-01-07
JP2017521068A (ja) 2017-08-03
EP3164504B1 (en) 2019-02-20
US20200199687A1 (en) 2020-06-25
EP3164504A1 (en) 2017-05-10
EP3530751A1 (en) 2019-08-28
JP6683633B2 (ja) 2020-04-22
US9994912B2 (en) 2018-06-12
US20180291466A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
ECSP17025787A (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
BR112017012222A2 (pt) métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
BR112017007965A2 (pt) método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit
MX2016007333A (es) Clasificacion de cancer de prostata.
ES2721477T3 (es) Materiales y métodos para evaluar la progresión del cáncer de próstata
EP4293358A3 (en) Volatile organic compounds as cancer biomarkers
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
ES2721907T3 (es) Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
EA201691499A1 (ru) Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
CO2019011359A2 (es) Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii
MX2018013621A (es) Metodo, matriz y uso de estos.
EP3686290A3 (en) Method and kits for identifying of cdk9 inhibitors for the treatment of cancer
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
Ju et al. Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy: a case study
MX2019008911A (es) Metodos, matrices y usos de estos.
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
WO2015095862A3 (en) Microrna biomarkers for ovarian cancer
MY193531A (en) Assays and methods for selecting a treatment regimen for a subject with leukemia
BR112019006862A2 (pt) dispositivo de análise e método para testagem de uma amostra
CL2023000509A1 (es) Composiciones y métodos para tratar la endometriosis
MY195697A (en) Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
WO2020123880A3 (en) Genomic rearrangements associated with prostate cancer and methods of using the same